Antiresorptive-cytocin efficiency of chondroprotective therapy of osteoarthritis and non-specific low back pain (results of ALBATROS study)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of the ALBATROS study, the purpose of which was to evaluate the antiresorptive-cytokine efficacy of chondroprotective therapy for osteoarthritis (OA) and non-specific lower back pain. The study showed that patients with OA and low back pain have elevated levels of cytokines and markers of bone resorption as a reflection of a single pathophysiological mechanism of damage to the musculoskeletal joint tissue. During the entire period of observation, positive dynamics with respect to decrease in resorption marker levels against the background of chondroprotective therapy with Alflutop was noted and statistically confirmed. The obtained results allow to consider chondroprotective therapy in the strategy of treatment of OA patients and low back pain in terms of its antiresorptive-cytokine efficacy.

Full Text

Restricted Access

About the authors

I. A Zolotovskaya

FSBEI HE "Samara State Medical University" of RMH

Email: zolotovskay@list.ru
PhD, Teaching Assistant at the Department of Hospital Therapy with Courses of Outpatient Therapy and Transfusiology

I. L Davydkin

FSBEI HE "Samara State Medical University" of RMH

References

  1. Pereira D., Ramos E., Branco J. Osteoarthritis. Acta Med. Port. 2015;28(1):99-106.
  2. Herrero-Beaumont G., Roman-Blas J.A., Bruyère O., Cooper C., Kanis J., Maggi S., Rizzoli R., Reginster J.Y. Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas. 2017;96:54-7.
  3. Zhang W., Nuki G., Moskowitz R.W., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18:476-99.
  4. Mastbergen S.C., Marijnissen A.C., Vianen M.E., van Roermund P.M., Bijlsma J.W., Lafeber F.P The canine «groove» model of osteoarthritis is more than simply the expression of surgically applied damage. Osteoarthritis Cartilage. 2006;14:39-46.
  5. Siebelt M., Waarsing J.H., Groen H.C., et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone. 2014;66:163-70.
  6. Duarte J.H. Osteoarthritis: alendronate treatment improves pathology in animal model of OA by blocking osteoclastic bone resorption. Nat. Rev. Rheumatol. 2014;10(8):446.
  7. Wang C.J., Huang C.Y., Hsu S.L., Chen J.H., Cheng J.H. Extracorporeal shockwave therapy in osteoporotic osteoarthritis of the knee in rats: an experiment in animals. Arthritis Res. Ther. 2014;16:139.
  8. De Lange-Brokaar B.J., Ioan-Facsinay A., Van Osch G.J., Zuurmond A.M., Schoones J., Toes R.E., Huizinga T.W., Kloppenburg M. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthr. Cartilage. 2012;20(12):1484-99.
  9. Mueller M.B., Tuan R.S. Anabolic/Catabolic balance in pathogenesis of osteoarthritis: identifying molecular targets. PM&R. 2011;3(6):3-11.
  10. Vangsness C.T., Burke W.S., Narvy S.J., MacPhee R.D., Fedenko A.N. Human knee synovial fluid cytokines correlated with grade of knee osteoarthritis - a pilot study. Bull. NYU Hosp. J. Dis. 2011;69(2):122-27.
  11. Altman R., Asch E., Bloch D., et al. Development of criteria for the classification and reporting of osteoarthritis:. Classification of osteoarthritis of the knee: Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthr. Rheum. 1986;29(8):1039-49.
  12. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 1988;15(12):1833-40.
  13. Smith B.H., Macfarlane G.J, Torrance N. Epidemiology of chronic pain, from the laboratory to the bus stop: time to add understanding of biological mechanisms to the study of risk factors in population-based research? Pain. 2007;127(1-2):5-10.
  14. van Hecke O., Torrance N., Smith B.H. Chronic pain epidemiology and its clinical relevance. Br. J. Anaesth. 2013;111(1):13-8.
  15. Hayes A.M., Place H.M. Chronic low back and left lower extremity pain in an elderly woman. J. Orthop. Sports Phys. Ther. 2013;43(9):674.
  16. Herkowitz H.N. Spine update. Degenerative lumbar spondylolisthesis. Spine (Phila Pa 1976). 1995;1;20(9):1084-90.
  17. Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J.P., Fahmi H. Role of proin flammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011;7(1):33-42.
  18. itman C., Mendis S., Barakat B., Loveland K.L. All in the family: TGF-beta family action in testis development. Reproduction. 2006;132(2):233-46.
  19. bee A.S., Ellman M.B., Yan D., Kroin J.S., Cole B.J., van Wijnen A.J., Im H.J. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527(2):440-720.
  20. Weiler C., Nerlich A.G., Bachmeier B.E., Boos N. Expression and distribution of tumor necrosis factor a in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine (Phila Pa 1976). 2005;30(1):44-53; discussion 54.
  21. Le Maitre C.L., Hoyland J.A., Freemont A.J. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. Arth. Res. Ther. 2007;9(4):77.
  22. Wuertz K., Haglund L. Inflammatory mediators in intervertebral disk degeneration and discogenic pain. Global Spine J. 2013;3(3):175-84.
  23. Lee S., Moon C.S., Sul D., Lee J., Bae M., Hong Y., Lee M., Choi S., Derby R., Kim B.J., Kim J., Yoon J.S., Wolfer L., Kim J., Wang J., Hwang S.W., Lee S.H. Comparison of growth factor and cytokine expression in patients with degenerated disc disease and herniated nucleus pulposus. Clin. Biochem. 2009;42(15):1504-11.
  24. Olariu L., Dumitriu B., Buse E., Pyatigorskaya N.V., Pavlov A. Влияние препарата Алфлутоп на факторы прогрессирования костно-суставной воспалительной патологии in vitro. Academy of Romanian Scientists Annals Series on Biological Sciences. 2015;4(2):7-18.
  25. Olariu L., Dumitriu B., Buse E., Pyatigorskaya N.V., Pavlov A. "In vitro" chondro-restitutive capacity of Alflutop proved on chondrocytes culture. Romanian Biotechnological Letters. 2016;22(6).
  26. Олариу Л., Димитриу Б., Мануэла Д., Павлов А., Пятигорская Н., Росоиу Н. Изменение in vitro механизмов остеоартрита с помощью препарата Алфлутоп. Академия румынских ученых.Вестник биологических наук. 2017;6(1):82-99.
  27. Herrero-Beaumont G., Roman-Blas J.A. Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents. Nat. Rev. Rheumatol. 2013;9(8):448-50

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies